Cannabinoid applications in glaucoma

Lastres-Becker, 2005, Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson¿s diseas, Neurobiol Dis, 19, 96, 10.1016/j.nbd.2004.11.009 Ramírez, 2005, Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activatio, J Neurosci, 25, 1904, 10.1523/JNEUROSCI.4540-04.2005 Panikashvili, 2001, An endogenous cannabinoid (2AG) is neuroprotective after brain injur, Nature, 413, 527, 10.1038/35097089 Amantea, 2007, Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradio, FEBS J, 274, 4464, 10.1111/j.1742-4658.2007.05975.x Centonze, 2007, The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosi, Int Rev Neurobiol, 82, 171, 10.1016/S0074-7742(07)82009-5 Macarrone, 2007, The endocannabinoid pathway in Huntington¿s disease: a comparison with other neurodegenerative disease, Prog Neurobiol, 81, 349, 10.1016/j.pneurobio.2006.11.006 Hepler, 1976, Ocular effects of marijuana smokin, 815 García-Valenzuela, 1995, Programmed cell death of retinal ganglion cells during experimental glaucom, Exp Eye Res, 61, 33, 10.1016/S0014-4835(95)80056-5 Dong, 2008, Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicit, Invest Ophthalmol Vis Sci, 49, 4515, 10.1167/iovs.08-2078 Dewey, 1986, Cannabinoid pharmacolog, Pharmacol Re, 38, 151 Gaoni, 1964, Isolation, structure and partial synthesis of an active constituent of hashis, J Am Chem Soc, 86, 1646, 10.1021/ja01062a046 Turner, 1989, Constituent of cannabis sativa L. A review of the natural constituen, Nat Procl, 43, 169, 10.1021/np50008a001 Freud, 2003, Role of endogenous cannabinoids in synaptic signalin, Physiol Rev, 83, 1017, 10.1152/physrev.00004.2003 Matsuda, 1997, Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissue, Exp Eye Res, 64, 707, 10.1006/exer.1996.0265 Bisogno, 1999, Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retin, Arch Biochem Biophys, 370, 300, 10.1006/abbi.1999.1410 Glaser, 2005, Endocannabinoids in the intact retina: 3H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamid, Vis Neursoci, 22, 693, 10.1017/S0952523805226020 Chen, 2005, Finding of endocannabinoids in human eye tissues: implications for glaucom, Biochem Biophys Res Commun, 330, 1062, 10.1016/j.bbrc.2005.03.095 He, 2007, Molecular and celular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cell, Mol Vis, 13, 1348 Chien, 2003, Effects of WIN-55212-2, a cannabinoid receptor agonist, on aqueous humor dynamic in monkey, Arch Ophthalmol, 126, 498 Struik, 2006, Cannabinoid agonist WIN 55212-2 speeds up the cone response to light offset in goldfish retin, Vis Neurosci, 23, 285, 10.1017/S0952523806232127 Van der Stelt, 2001, Exogenous anandamide protects rat brain against acute neuronal injury in viv, J Neurosci, 278, 157 Matsuda, 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDN, Nature, 346, 56156, 10.1038/346561a0 Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoid, Nature, 365, 61, 10.1038/365061a0 Breivogel, 2001, Evidence for a new G protein-coupled cannabinoid receptor in mouse brai, Mol Pharmacol, 60, 155, 10.1124/mol.60.1.155 Porcella, 1998, Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuan, Brain Res Mol Brain Res, 58, 240, 10.1016/S0169-328X(98)00105-3 Straiker, 1999, Localization of cannabinoid CB1 receptors in the human anterior eye and retin, Invest Ophthalmol Vis Sci, 40, 2442 Yazulla, 1999, Immunocytochemical localization of cannabinoid CB1 receptor and fatty acidamide hydrolase in rat retin, J Comp Neurol, 415, 80, 10.1002/(SICI)1096-9861(19991206)415:1<80::AID-CNE6>3.0.CO;2-H Romano, 2006, Cannabinoid agonists induce relaxation in the bovine ophthalmic artery for CB1 receptors, nitric oxide and potassium channel, Br J Pharmacol, 147, 917, 10.1038/sj.bjp.0706687 Green, 1998, Marijuana smoking vs cannabinoids for glaucoma therap, Arch Ophthalmol, 116, 1433, 10.1001/archopht.116.11.1433 Hepler, 1976, Experiences with administration of marihuana to glaucoma patient, 63 Cooler, 1976, The effect of delta-9-tetrahydrocannabinol on intraocular pressure in human, 77 Tomida, 2006, Effect of sublingual application of cannabinoids on intraocular pressure: a pilot stud, J Glaucoma, 15, 349, 10.1097/01.ijg.0000212260.04488.60 Naveh, 2000, A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbit, Graefes Arch Exp Ophthalmol, 238, 334, 10.1007/s004170050361 Porcella, 2001, The synthetic cannabinoid WIN 55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapie, Eur J Neurosci, 13, 409, 10.1046/j.0953-816X.2000.01401.x Stamer, 2001, Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissue, Eur J Pharmacol, 431, 277, 10.1016/S0014-2999(01)01438-8 Colasanti, 1990, A comparison of the ocular and central effects of delta-9-tetrahydrocannabinol and cannabigero, J Ocular Pharmacol, 6, 259, 10.1089/jop.1990.6.259 Njie, 2006, Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptor to enhance aqueous humor outflow facilit, Invest Ophthalmol Vis Sc, 47, 1999, 10.1167/iovs.05-0729 ltmanns, 2008, Topical WIN 55212-2 alleviates intraocular hypertension in rats through a CB1 receptor-mediated mechanism of actio, J Ocul Pharmacol Ther, 24, 104, 10.1089/jop.2007.0074 Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid recepto, Science, 258, 1946, 10.1126/science.1470919 Beilin, 2000, Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoi, J Ocul Pharmacol Ther, 16, 217, 10.1089/jop.2000.16.217 Howlett, 1990, The cannabinoid receptor: biochemical, anatomical and behavioral characterizatio, Trends Neurosci, 13, 40, 10.1016/0166-2236(90)90124-S Galve-Roperh, 2008, Mechanisms of control of neuron survival by the endocannabinoid syste, Curr Pharm Des, 14, 2279, 10.2174/138161208785740117 Marsicano, 2003, CB1 cannabinoid receptors on-demanmd defense against excitotoxicit, Science, 302, 84, 10.1126/science.1088208 Khaspekov, 2004, Involvement of brain-derived neurotrophic factor in cannabinoid-dependent protection against excitotoxicit, Eur J Neurosci, 19, 1691, 10.1111/j.1460-9568.2004.03285.x Molina-Holgado, 2002, Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signalin, J Neurosci, 22, 9742, 10.1523/JNEUROSCI.22-22-09742.2002 Eljaschewitsch, 2006, The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cell, Neuron, 49, 67, 10.1016/j.neuron.2005.11.027 Veldhuis, 2003, Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxcity in the rat: role of vanilloid receptors and lipoxygenase, J Neurosci, 23, 4127, 10.1523/JNEUROSCI.23-10-04127.2003 Liu, 2006, biosynthetic pathway for anandamid, Proc Natl Acad Sci US, 103, 13345, 10.1073/pnas.0601832103 Vink, 2009, Multifunctional drugs for head injur, Neurotherapeutics, 6, 28, 10.1016/j.nurt.2008.10.036 Nucci, 2005, Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in ra, Neurotoxicology, 26, 935, 10.1016/j.neuro.2005.06.002 Honkanen, 2003, Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectom, Arch Ophthalmol, 121, 183, 10.1001/archopht.121.2.183 El-Remessy, 2003, Neuroprotective effect of (-)Δ9- tetrahydrocannabinol and cannabidiol in N-Methyl-DAspartate-induced retinal neurotoxicity, Am J Pathol, 163, 1977, 10.1016/S0002-9440(10)63558-4 Sisk, 1985, Histologic changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamat, Graefes Arch Clin Exp Ophthalmol, 223, 250, 10.1007/BF02153655 Samy, 1994, Toxicity of chronic glutamate administration to retin, Invest Ophthalmol Vis Sci, 35, 497 Glovinsky, 1993, Foveal ganglion cell loss is size dependent in experimental glaucom, Invest Ophthalmol Vis Sci, 34, 395 Marsicano, 2002, Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB, J Neurochem, 80, 448, 10.1046/j.0022-3042.2001.00716.x Twitchell, 1997, Cannabinoids inhibit Nand P/Q-type calcium channel in cultured rat hyppocampal neuron, J Neurophysiol, 78, 43, 10.1152/jn.1997.78.1.43 Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamid, Br J Pharmacol, 134, 845, 10.1038/sj.bjp.0704327 Sugiura, 1998, Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator, J Biochem Biophys Res Commun, 243, 838, 10.1006/bbrc.1998.8187 Quigley, 1984, Blood vessels of the glaucomatous optic disk in experimental primate and human eye, Invest Ophthalmol Vis Sci, 25, 918 Hafez, 2003, Evaluation of optic nerve head and peripapillary retinal blood flow in glaucoma patients Ocular hypertension and normal subject, Am J Ophthalmol, 136, 1022, 10.1016/S0002-9394(03)00632-9 Mukhopadhyay, 2002, Anandamideinduced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independen, Am J Physiol, 282, 2046 Merritt, 1982, Glaucoma, hypertension and marijuan, J Natl Med Assoc, 74, 715 Plange, 2007, Dronabinol and retinal hemodynamics in human, Am J Ophthalmol, 143, 173, 10.1016/j.ajo.2006.07.053 Green, 1978, Effects of delta-9-tetrahydrocannabinol on ocular blood flow and aqueous humor formatio, Exp Eye Res, 26, 65, 10.1016/0014-4835(78)90152-5 Rosenkrantz, 1979, Effects of cannabis on lung, 279 Pertwee, 2000, Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and developmen, Exp Opin Invest Drugs, 9, 1553, 10.1517/13543784.9.7.1553 Martín, 1986, Cellular effects of cannabinoid, Pharmacolog Rev, 38, 45 Hodges, 1997, Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbit, Ophthalmic Res, 29, 1, 10.1159/000267984 Colasanti, 1984, Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigero, Exp Eye Res, 39, 251, 10.1016/0014-4835(84)90013-7 Hosseini, 2006, Chronic topical administration of WIN-55212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effect, Exp Eye Res, 82, 753, 10.1016/j.exer.2005.09.017 Pate, 1988, Effect of the CB1 receptor antagonist, SR141716A, on cannabinoidinduced ocular hypotension in normotensive rabbit, Life Sci, 63, 2181, 10.1016/S0024-3205(98)00499-8 Pate, 1996, Effects of topical anandamide on intraocular pressure in normotensive rabbit, Life Sci, 58, 1849, 10.1016/0024-3205(96)00169-5 Green, 1982, Ocular effects of topical administration of delta 9-tetrahydrocannabinoid in ma, Arch Ophthalmol, 100, 265, 10.1001/archopht.1982.01030030267006 Yazulla, 2008, Endocannabinoids in the retina: from marihuana to neuroprotectio, Prog Retin Eye Res, 27, 501, 10.1016/j.preteyeres.2008.07.002 Pinar-Sueiro, 2009, Role of cannabinoids in glaucom, Arch Soc Esp Oftalmol, 84, 487 Nucci, 2008, Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure to neurprotectio, Prog Brain Res, 173, 451, 10.1016/S0079-6123(08)01131-X Candrall, 2007, Neuroprotective and intraocular pressure-lowering effects of (-)Delta-9-tetrahydrocannibol in a rat model of glaucom, Ophthalmic Res, 39, 69, 10.1159/000099240